Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17675669 | 0.82 | CYP19A1 (0.42) | CYP19A1ALDH1A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL5972481 | 0.81 | CYP19A1 (0.57) | CYP19A1ALDH1A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL11224914 | 0.80 | CYP19A1 (0.48) | CYP19A1ALDH1A1CYP26A1CYP3A4MAPT | |
| SCHEMBL9223087 | 0.72 | CYP19A1 (0.57) | CYP19A1ALDH1A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL14863070 | 0.70 | CYP17A1 (0.52) | CYP19A1ALDH1A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL5564403 | 0.69 | CYP17A1 (0.53) | CYP19A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL17315106 | 0.68 | CYP19A1 (0.61) | CYP19A1ALDH1A1CYP26A1CYP3A4CYP17A1 | |
| SCHEMBL3560288 | 0.68 | CYP19A1 (0.61) | CYP19A1CYP26A1CYP3A4SLC6A3 | |
| SCHEMBL4185220 | 0.68 | MAPT (0.48) | ALDH1A1MAPT | |
| SCHEMBL11333169 | 0.68 | CYP19A1 (0.52) | CYP19A1CYP26A1CYP3A4CYP17A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | CYP19A1 2912/4885ALDH1A1 872/4885CYP26A1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.